ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

5 Stocks with Unusually Large Short Interest

Short Squeeze Stock Market Share Prices Increase Sell Make Money 3d Illustration

With the broader market reaching new all-time highs, primarily driven by the tech sector and specifically semiconductor stocks fueled by the hype surrounding AI, the spotlight is once again beginning to shine on high short-interest stocks

These companies, facing elevated levels of short interest, have been subject to intense scrutiny and volatility as investors and short sellers engage in a tug-of-war over their stock prices. So, with investor confidence and speculation significantly on the rise, let’s delve into five of the highest-shorted stocks currently in the market and why it may be time to learn how to short stocks

Upstart Holdings (NASDAQ: UPST)

Upstart is a lending platform in the United States that employs AI technology to make credit decisions. It offers loans for various purposes, and leverages advanced algorithms to assess creditworthiness beyond traditional factors.

The overwhelming bearish sentiment appears aligned with the market on UPST, as the stock has fallen over 35% year-to-date and almost 20% over the last month. UPST is one of the lowest-rated stocks, with a reduce rating based on nine analyst ratings. The short interest has remained severely elevated despite a significant selloff in recent months. As of February 15, 35.64% of the float was sold short, equalling almost 26 million shares positioned short. Should momentum shift to the upside, the considerable short interest might exacerbate the move.

Carvana (NYSE: CVNA)

Carvana is an online platform primarily operating in the United States that is focused on automotive retail. The company facilitates buying, selling, and financing vehicles through its website, offering customers a simplified and digital car purchasing experience.

Thanks to its elevated short interest and recent earnings, the online automotive retailer's stock has posted impressive gains recently. Year-to-date shares are up 46% and a whopping 770% over the previous year. The sentiment surrounding CVNA is also overwhelmingly bearish, with recent insider selling, a consensus rating of reduce, and a price target forecasting a 43% downside. As of February 15, the short interest in the stock was 16.51% or 33.3 million shares positioned short.

C3.ai (NYSE: AI)

C3.ai focuses on enterprise AI software solutions. Its offerings span predictive maintenance, fraud detection, and supply chain optimization and cater to various industries.

Analysts are not as bearish on the name as on the above two, with a consensus analyst rating of hold based on ten analyst ratings. However, the bearish sentiment is present, with insiders selling stock during the previous quarter, a heightened short interest, and the name featuring on the lowest-rated stocks list. As of February 15, 28.81% of the float in AI was sold short, totaling 34.5 million shares. 

Arbor Realty Trust (NYSE: ABR)

Arbor Realty is a real estate investment trust headquartered in Uniondale, New York. Led by Chairman and CEO Ivan Kaufman, the company invests in diverse structured finance assets within the U.S. real estate market. Focusing on multifamily, single-family rental, and commercial real estate sectors, Arbor manages a portfolio exceeding $42 billion and originates over $16 billion in loans annually.

Unlike the above stocks, ABR has positive sentiment despite highly high short interest. The consensus analyst rating for ABR is hold, and the consensus price target is $15.67, which sees almost 22% upside for the stock. However, as of February 15, the short interest was up 8.56% over the previous month to 36.8%, making ABR one of the highest shorted stocks. As of February 15, 69.3 million shares were sold short.

ImmunityBio (NYSE: IBRX)

ImmunityBio, Inc. is a clinical-stage biotechnology company dedicated to advancing therapies and vaccines to bolster the immune system against cancer and infectious diseases. The company strives to enhance patient outcomes through innovative immunotherapy and cell therapy platforms by fostering robust and sustained immune responses.

IBRX, like ABR, is one of the highest-shorted stocks on the NYSE, with a 36.07% short float as of February 15. Over the prior month, that figure increased by 7.31%, with the total number of shares sold short now at a staggering 43.9 million. With only one analyst rating, the stock has a hold rating and a price target forecasting over 21% of downside. 

Recent Quotes

View More
Symbol Price Change (%)
AMZN  254.00
+0.00 (0.00%)
AAPL  269.05
+0.00 (0.00%)
AMD  259.65
+0.00 (0.00%)
BAC  53.56
+0.00 (0.00%)
GOOG  284.12
+0.00 (0.00%)
META  637.71
+0.00 (0.00%)
MSFT  517.03
+0.00 (0.00%)
NVDA  206.88
+0.00 (0.00%)
ORCL  257.85
+0.00 (0.00%)
TSLA  468.80
+0.43 (0.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.